Drug intelligence / Profile preview

CLPH-701

Development stage: Unknown
Lead developer: Cellphire Therapeutics
Modality: Cell Therapies

Overview

CLPH-701 is a cell therapy developed by Cellphire, Inc. It involves platelet-enabled drug delivery, where biologic molecules are loaded and stabilized into platelets. This technology has applications in various disease states, with Cellphire having in-vitro and preliminary in-vivo data using stabilized Doxorubicin-loaded platelets.

Other names: CLPH701CLPH-701CLPH 701

Beyond the preview

Go deeper on CLPH-701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLPH-701.

Explore the full profile